RUNX2 and myelodysplastic syndrome: Additionally, the levels of two key factors for osteogenic differentiation, Osterix and RunX2, were found to be reduced in BMMSCs, and the number of osteoblasts was significantly decreased in patients with low-risk MDS, indicating impaired osteogenic differentiation of MDS-derived BMMSCs [14,15].